Adage Capital Partners
DNTH icon

Adage Capital Partners’s Dianthus Therapeutics DNTH Stock Holding History

Adage Capital Partners’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.4M Buy
+160,000
New +$9.27M 0.02% 609
2025
Q4 		– Sell
-77,000
Closed -$3.03M – 936
2025
Q3 		$3.03M Sell
77,000
-108,000
-58% -$2.76M ﹤0.01% 779
2025
Q2 		$3.45M Sell
185,000
-4,000
-2% -$75K 0.01% 735
2025
Q1 		$3.43M Buy
189,000
+9,000
+5% +$198K 0.01% 731
2024
Q4 		$3.92M Buy
+180,000
New +$4.63M 0.01% 738
2024
Q3 		– Sell
-250,000
Closed -$6.47M – 893
2024
Q2 		$6.47M Sell
250,000
-48,000
-16% -$1.15M 0.01% 680
2024
Q1 		$8.94M Buy
+298,000
New +$6.48M 0.02% 621
2023
Q1 		– Sell
-54,291
Closed -$343K – 937
2022
Q4 		$343K Buy
54,291
+3,125
+6% +$55.3K ﹤0.01% 869
2022
Q3 		$1.15M Buy
51,166
+7,044
+16% +$193K ﹤0.01% 885
2022
Q2 		$847K Buy
44,122
+19,879
+82% +$491K ﹤0.01% 929
2022
Q1 		$1.13M Buy
+24,243
New +$1.32M ﹤0.01% 931

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Adage Capital Partners's DNTH Position: Q1 2026 in Review

Adage Capital Partners opened a new position in Dianthus Therapeutics (DNTH) in Q1 2026: 160,000 shares worth $13.4M. The stake represents 0.02% of the portfolio and ranks #609 among its holdings. This is a return to the name: Adage Capital Partners previously reported a position in DNTH as recently as Q3 2025.

Adage Capital Partners first reported a position in DNTH in Q1 2022 and has held it in 11 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Adage Capital Partners held 160,000 shares of Dianthus Therapeutics worth $13.4M as of Q1 2026.
  • Dianthus Therapeutics was a new Adage Capital Partners position in Q1 2026.
  • Dianthus Therapeutics made up 0.02% of Adage Capital Partners's portfolio in Q1 2026, its #609 holding.
  • Adage Capital Partners first reported a position in Dianthus Therapeutics in Q1 2022 and has held it in 11 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.